Ticker

FDA assigned PDUFA target action date of January 29, 2027 No advisory committee meeting expected BOSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for…

Praxis Precision Medicines, Inc. remains a Strong Buy, driven by two NDA submissions and pipeline expansion opportunities targeting essential tremor and developmental and epileptic encephalopathies. The company's relutrigine achieved a 46% placebo-adjusted reduction in motor seizure frequency for SCN2A/SCN8A DEE and is under FDA priority review with a PDUFA date of September 27, 2026. Pipeline expansion includes…

Praxis said elsunersen demonstrated a placebo-adjusted seizure reduction from baseline of 77% (p=0.015) in pediatric patients with SCN2A developmental and epileptic encephalopathy.

Elsunersen demonstrated placebo-adjusted seizure reduction from baseline of 77% (p=0.015) 71% of elsunersen-treated patients achieved >50% seizure reduction by period 6, with sustained benefit observed in the open-label extension for up to one year 100% of elsunersen patients - and none on placebo - had additional improvements, including sleep, motor function, muscle tone and attention No treatment-emergent or…

SG Americas Securities LLC lessened its position in Praxis Precision Medicines, Inc. (NASDAQ: PRAX) by 26.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 9,965 shares of the company's stock after selling 3,531 shares during the quarter.